In the published article, there was an error in the Funding statement. It originally stated:
“The authors declare that this study received funding from Pfizer. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.”
The Funding statement has now been removed.
In the published article, there was an error in the Conflict of interest Statement. It originally stated:
“Authors GR and ZA-T were employed by RxTarget Ltd.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The correct Conflict of interest statement appears below.
“GR and ZA-T are employees of RxTarget Ltd., which was a paid contractor to Pfizer in connection with the development of this manuscript and was responsible for data curation and statistical analysis. This study was sponsored by Pfizer. Medical writing support was provided by Zsófia Barcza at Syntesia Medical Communications Ltd. and was funded by Pfizer. The funder had the following involvement in the study: administrative support and review regarding study design, statistical analysis, and manuscript development.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
chronic myeloid leukemia, real-word evidence, tyrosine kinase inhibitors, treatment outcome, overall survival
Citation
Batar P, Alizadeh H, Rokszin G, Abonyi-Toth Z and Demeter J (2024) Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary. Pathol. Oncol. Res. 30:1611758. doi: 10.3389/pore.2024.1611758
Received
06 March 2024
Accepted
07 March 2024
Published
21 March 2024
Approved by
Pathology and Oncology Research Editorial Office, Frontiers Media SA, Switzerland
Volume
30 - 2024
Updates
Copyright
© 2024 Batar, Alizadeh, Rokszin, Abonyi-Toth and Demeter.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Peter Batar, pbatar@med.unideb.hu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.